FDA approves Rasonque for pancreatic cancer: When it's available and cost

The FDA has approved Rasonque, an oral treatment targeting RAS proteins for advanced pancreatic cancer, significantly extending survival for patients with metastatic disease where other treatments have failed. The drug is now available in the US with a wholesale cost of $39,800 per month and is expected to be covered under Medicare Part D, though patient out-of-pocket costs may vary.

This Wire brief sits within Fusion42's coverage of Health, and 32 sources have reported it between 26 Aug 2026 and 27 Aug 2026.